American Society of Hirudotherapy

Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition

Research article published in The EMBO journal (1990)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentGrtter MG et al. · The EMBO journal, 1990

Abstract

Thrombin is a serine protease that plays a central role in blood coagulation. It is inhibited by hirudin, a polypeptide of 65 amino acids, through the formation of a tight, noncovalent complex. Tetragonal crystals of the complex formed between human alpha-thrombin and recombinant hirudin (variant 1) have been grown and the crystal structure of this complex has been determined to a resolution of 2.95 A. This structure shows that hirudin inhibits thrombin by a previously unobserved mechanism. In contrast to other inhibitors of serine proteases, the specificity of hirudin is not due to interaction with the primary specificity pocket of thrombin, but rather through binding at sites both close to and distant from the active site. The carboxyl tail of hirudin (residues 48-65) wraps around thrombin along the putative fibrinogen secondary binding site. This long groove extends from the active site cleft and is flanked by the thrombin loops 35-39 and 70-80. Hirudin makes a number of ionic and hydrophobic interactions with thrombin in this area. Furthermore hirudin binds with its N-terminal three residues Val, Val, Tyr to the thrombin active site cleft. Val1 occupies the position P2 and Tyr3 approximately the position P3 of the synthetic inhibitor D-Phe-Pro-ArgCH2Cl. Thus the hirudin polypeptide chain runs in a direction opposite to that expected for fibrinogen and that observed for the substrate-like inhibitor D-Phe-Pro-ArgCH2Cl.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceBinding SitesComputer GraphicsCrystallizationHirudinsHumansModels, MolecularMolecular Sequence DataOligopeptidesProtein ConformationSerine Proteinase InhibitorsThrombin

Summary

Thrombin is a serine protease that plays a central role in blood coagulation.

Why This Matters for Hirudotherapy

This study determined the crystal structure of the complex formed between human alpha-thrombin and recombinant hirudin (variant 1) at 2.95 Å resolution. The abstract describes hirudin as a 65-amino-acid polypeptide that inhibits thrombin through a novel mechanism: rather than engaging the primary specificity pocket, hirudin binds at sites both near and distant from the active site, with its C-terminal tail wrapping along the fibrinogen secondary binding site and its N-terminal residues occupying the active-site cleft. This structural work is relevant to understanding thrombin inhibition at a molecular level. However, the abstract does not mention leeches, leech saliva, or medicinal leeches, and this is a preclinical structural biology study with no direct application to live leech therapy.

Citation

Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition

Grtter MG et al. · The EMBO journal, 1990

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.